ACHILLES THERAPEUTICS PLC

Insiders Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2024 BST			5-day change	1st Jan Change
0.92 ^USD	0.00%		+0.12%	+3.49%

05-08	Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-05	Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Achilles Therapeutics plc Announces Management Appointments, Effective July 1, 2022	30/06/22	CI
Achilles Therapeutics plc Announces Management Changes	04/05/22	CI
Achilles Therapeutics plc Appoints Alena Gros and Ben Creelan to Its Scientific Advisory Board	07/02/22	CI
Achilles Therapeutics plc Announces Changes to Its Board	03/05/21	CI
Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager	08/01/21	CI
Achilles Therapeutics Appoints Lee M. Stern as VP, IR & External Communications	07/12/20	CI
Achilles Therapeutics Announces the Appointment of Robert Coutts as Chief Financial Officer	01/12/20	CI
Achilles Therapeutics Appoints Professor Karl Peggs as Chief Medical Officer with Effect from January 4, 2021	07/10/20	CI
Achilles Therapeutics Announces Formation of Scientific Advisory Board	13/05/20	CI
Achilles Therapeutics Announces Appointment of Carsten Boess as Non-Executive Director to Its Board	07/04/20	CI
Achilles Therapeutics Appoints Sergio Quezada as Chief Scientific Officer, Effective 6 April 2020	17/03/20	CI
Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer	21/10/19	CI
Achilles Therapeutics Adds Two Leading Life Science Executives to the Board	03/09/19	CI
Achilles Therapeutics Appoints Markus Dangl as Chief Scientific Officer	12/02/19	CI
Achilles Therapeutics Appoints Dr. Edwin Moses as Chairman of Its Board of Directors and Dr. Iraj Ali as Chief Executive Officer	10/12/18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer